296
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Synthesis of Novel Pyrazolyl-1,3,4-Thiadiazole Analogues

, , &
Pages 1249-1259 | Received 01 Feb 2020, Accepted 20 May 2020, Published online: 29 May 2020

References

  • M. Li, and B. Zhao, “Progress of the Synthesis of Condensed Pyrazole Derivatives (from 2010 to Mid-2013),”European Journal of Medicinal Chemistry 85, (2014): 311–40.
  • A. Radwan, M. Khalid, H. Amer, and M. Alotaibi, “Anticancer and Molecular Docking Studies of Some New Pyrazole-1-Carbothioamide Nucleosides,” Biointerface Research in Applied Chemistry 9, (2019): 4642–8.
  • M. Ehab, A. E. Gedawy, A. M. Kassab, and K. El, “Design, Synthesis and Biological Evaluation of Novel Pyrazole Sulfonamide Derivatives as Dual COX-2/5-LOX Inhibitors,”European Journal of Medicinal Chemistry 189, (2020): 112066.
  • A. M. Vijesh, A. M. Isloor, P. Shetty, S. Sundershan, and H. K. Fun, “New Pyrazole Derivatives Containing 1,2,4-triazoles and Benzoxazoles as Potent Antimicrobial and Analgesic Agents,” European Journal of Medicinal Chemistry 62, (2013): 410–5.
  • R. Neidiane, P. R. Trindade, L. M. Lopes, J. O. Naves, P. H. Fajemiroye, N. O. Alves, L. M. Amaral, A. C. S. Liao, C. H. Rebelo, V. A. Castro, et al. “The Newly Synthesized Pyrazole Derivative 5-(1-(3 Fluorophenyl)-1H-Pyrazol-4-yl)-2H-Tetrazole Reduces Blood Pressure of Spontaneously Hypertensive Rats via NO/cGMO Pathway,” Frontiers in Physiology. 9, (2018): 1073–83.
  • D. C. Malvar, R. T. Ferreira, R. A. de Castro, L. L. de Castro, A. C. Freitas, E. A. Costa, I. F. Florentino, J. C. Mafra, G. E. de Souza, and F. A. Vanderlinde, “Antinociceptive, anti-Inflammatory and Antipyretic Effects of 1.5-Diphenyl-1H-Pyrazole-3-Carbohydrazide, a New Heterocyclic Pyrazole Derivative,”Life Sciences 95no. 2 (2014): 81–8.
  • G. M. Reddy, R. G. Jarem, V. Z. Grigory, S. Gundala, and N. B. Reddy, “Pyranopyrazoles as Efficient Antimicrobial Agents: Green, One Pot and Multicomponent Approach,” Bioorganic Chemistry 82, (2019): 324–31.
  • V. L. M. Silva, J. Elguero, and A. M. S. Silva, “Current Progress on Antioxidants Incorporating the Pyrazole Core,”European Journal of Medicinal Chemistry 156, (2018): 394–429.
  • A. Ansari, A. Ali, M. Asif, and S. Shamsuzzaman, “Biologically Active Pyrazole Derivatives,”New Journal of Chemistry 41no. 1 (2017): 16–41.
  • G. Satish, R. A. Srinivasa, L. P. Jeevan, R. V. Rajeswar, and P. Santhosh, “An Efficient Synthesis of Pyrazolyl‐1,2,3‐Thiadiazoles via Hurd–Mori Reaction,” Journal of Heterocyclic Chemistry 56, (2019): 2163–9.
  • G. Serban, O. Stanasel, E. Serban, and S. Bota, “ 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents,”Drug Design, Development and Therapy 12, (2018): 1545–66.
  • G. Serban, “Synthetic Compounds with 2-Amino-1,3,4-Thiadiazole Moiety against Viral Infections,”Molecules 25no. 4 (2020): 942–64.
  • T. A. Farghaly, M. A. Abdallah, G. S. Masaret, and Z. A. Muhammad, “New and Efficient Approach for Synthesis of Novel bioactive [1,3,4]thiadiazoles incorporated with 1,3-thiazole moiety,”European Journal of Medicinal Chemistry 97, (2015): 320–33.
  • N. Chidananda, B. Poojary, V. Sumangala, N. S. Kumari, P. Shetty, and T. Arulmoli, “Facile Synthesis, Characterization and Pharmacological Activities of 3,6-Disubstituted 1,2,4-Triazolo[3,4-b][1,3,4]Thiadiazoles and 5,6-Dihydro-3,6-Disubstituted-1,2,4-Triazolo[3,4-b][1,3,4]Thiadiazoles,” European Journal of Medicinal Chemistry. 51, (2012): 124–36.
  • E. E. Oruc, S. Rollas, F. Kandemirli, N. Shvets, and A. S. Dimoglo, “1,3,4-thiadiazole Derivatives. Synthesis, Structure Elucidation, and Structure-Antituberculosis Activity Relationship Investigation,”Journal of Medicinal Chemistry 47, no. 27 (2004): 6760–7.
  • A. N. Y. Megally, and M. M. Kamel, “Synthesis and Anticancer Evaluation of 1,3,4-Oxadiazoles, 1,3,4-Thiadiazoles, 1,2,4-Triazoles and Mannich Bases,”Chemical & Pharmaceutical Bulletin 63, no. 5 (2015): 369–76.
  • (a) K. M. Dawood, and T. A. Farghaly, “Thiadiazole inhibitors: A patent review. Expert Opinion on Therapeutic Patents 27 (2017): 477–505. (b) G. Serban, “Future prospects in the treatment of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasis,” Molecules, 24 (2019): 1557.
  • (a) L. Brunton, B. Chabner, and B. G. Knollman, Goodman & Gilman's the Pharmacological Basis of Therapeutics (MacGraw-Hill: New York, NY, USA, 2010). (b) V. R. Pattabiraman, and J. W. Bode, “Rethinking amide bond synthesis,” Nature, 480 (2011): 471–479. (c) A. A. Kaspar, and J. M. Reichert, “Drug future directions for peptide therapeutics development,” Discovery Today, 18 (2013): 807–817. (d) D. G. Brown, and J. Bostrom, “Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?” Journal of Medicinal Chemistry. 59 (2016): 4443–4458.
  • O. Turan, E. Erdal, and M. Olcay, “Use of Lawesson’s Reagent in Organic Syntheses,” Chemical Reviews. 107, (2007): 5210–78.
  • A. A. Kiryanov, P. Sampson, and A. J. Seed, “Synthesis of 2-alkoxy-substituted thiophenes, 1,3-thiazoles, and related S-heterocycles via Lawesson's reagent-mediated cyclization under microwave irradiation: applications for liquid crystal synthesis,”The Journal of Organic Chemistry 66, no. 23 (2001): 7925–9.
  • E. Aparna, K. M. Lokanatha Rai, M. Sureshbabu, R. L. Jagadish, S. L. Gaonkar, and K. Byrappa, “Synthesis of Thioesters and Thioamides under Solvothermal Condition Using Thiourea as Thionating Agent,”Journal of Materials Science 41, no. 5 (2006): 1391–3.
  • A. B. Charette, and M. Grenon, “Mild Method for the Conversion of Amides to Thioamides,”The Journal of Organic Chemistry 68, no. 14 (2003): 5792–4.
  • R. Venkat Ragavan, V. Vijayakumar, and N. Suchetha Kumari, “Synthesis and Antimicrobial Activities of Novel 1,5-Diaryl Pyrazoles,”European Journal of Medicinal Chemistry 45, no. 3 (2010): 1173–80.
  • V. Ines, P. R. Andrea, M. M. Kata, B. Karmen, and B. Branimir, “Synthesis and Biological Validation of Novel Pyrazole Derivatives with Anticancer Activity Guided by 3D-QSAR Analysis,” Bioorganic and Medicinal Chemistry. 20, (2012): 2101–10.
  • N. P. Rai, V. K. Narayanaswamy, S. Shashikanth, and P. N. Arunachalam, “Synthesis, Characterization and Antibacterial Activity of 2-[1-(5-Chloro-2-Methoxy-Phenyl)-5-Methyl-1H-Pyrazol-4-yl]-5-(Substituted-Phenyl)-[1,3,4]Oxadiazoles,”European Journal of Medicinal Chemistry 44, no. 11 (2009): 4522–7.
  • A. A. Bekhit, H. M. A. Ashour, Y. S. A. Ghany, A. E. D. A. Bekhit, and A. Baraka, ” “Synthesis and Biological Evaluation of Some Thiazolyl and Thiadiazolyl Derivatives of 1H-Pyrazole as anti-Inflammatory Antimicrobial Agents,”European Journal of Medicinal Chemistry 43, no. 3 (2008): 456–63.
  • Rahmi Kasımoğulları, Metin Bülbül, B. Seçkin Arslan, and Başak Gökçe, “Seckin Arslan, B.; Basak G. “Synthesis, Characterization and Antiglaucoma Activity of Some Novel Pyrazole Derivatives of 5-Amino-1,3,4-Thiadiazole-2-Sulfonamide,”European Journal of Medicinal Chemistry 45, no. 11 (2010): 4769–73.
  • S. Ningaiah, U. K. Bhadraiah, S. Keshavamurthy, and C. Javarasetty, “Novel Pyrazoline Amidoxime and Their 1,2,4-oxadiazole analogues: synthesis and pharmacological screening,”Bioorganic & Medicinal Chemistry Letters 23, no. 16 (2013): 4532–8.
  • Bruker. APEX2 and SAINT. (Madison, Wisconsin, USA: Bruker AXS Inc., 2009).
  • G. M. Sheldric, “A Short History of SHELX,” Acta Cryst A64, (2008): 112–22.
  • (a) Wagner, R. B.; Zook, H. D. Synthetic organic chemistry (John Willey & Sons, New York, 1953), 569. b) Yale, H. L.; Losee, K.; Martins, J.; Holsing, M.; Perry, F. M.; Bernstein, J. “Chemotherapy of Experimental Tuberculosis. VIII. The Synthesis of Acid Hydrazides, their Derivatives and Related Compounds,” Journal of the American Chemical Society 75, (1953): 1933–1942.
  • For appropriate precautions when handling H2S, see: Prudent Practices in the Laboratory: Handling and Disposal of Chemicals (Washington, DC: National Research Council, National Academy Press, 1995), 342–343.
  • K. B. Umesha, and K. M. L. Rai, “Synthesis and Antimicrobial Activity of Pyrazole Derivatives via 1, 3-Dipolar Cycloaddition of Nitrile Imines with Ethyl Acetoacetate,” Bulg. Chem. Commun 42, (2010): 11–5.
  • A. L. Spek, “Structure Validation in Chemical Crystallography,”Acta Crystallographica. Section D, Biological Crystallography 65, no. Pt 2 (2009): 148–55.
  • (a) CCDC 968764 for (4a) and CCDC 967458 for (7a) contain the supplementary crystallographic data for this paper. They can be obtained free of charge from The Cambrige Crystallographic Data Centere via www.ccdc.cam.ac.uk/data_request/cif. (b) Chandra, N. Srikantamurthy, Shamantha Kumar, B. H., Doreswamy K. B. Umesha, and M. Mahendra, “N’-Benzoyl-5-methyl-1,3-diphenyl-1H-pyrazole-4-carbohydrazide,” Acta Crystallogr E69 (2013): o1769. (c) Chandra, S. S., Mahesh, N. Srikantamurthy, K. B. Umesha, K. Palani, M. Mahendra, “5-Methyl-1,3-diphenyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrazole-4-carboxamide,” Acta Crystallogr E69 (2013): o1736.
  • P. C. Michel, and I. L. Matthew, “Thionation Reactions of Lawesson’s Reagents,” Tetrahedron 41, (1985): 5061–87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.